Lucid Diagnostics Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Lucid Diagnostics Inc. (LUCD) reported Revenue from Contract with Customer, Excluding Assessed Tax of $1.21 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-11-12
- Lucid Diagnostics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.21M, a 3.33% increase year-over-year.
- Lucid Diagnostics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $1.16M, a 19.16% increase year-over-year.
- Lucid Diagnostics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $828.00K, a 17.28% decline year-over-year.
- Lucid Diagnostics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-12-31 was $1.20M, a 15.10% increase year-over-year.
- Lucid Diagnostics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $4.35M, a 79.00% increase from fiscal 2023.
- Lucid Diagnostics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $2.43M, a 544.03% increase from fiscal 2022.
- Lucid Diagnostics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $377.00K, a 24.60% decline from fiscal 2021.
- Lucid Diagnostics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $500.00K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-09-30 | $1.21M 10-Q · filed 2025-11-12 | $2.37M derived: sum of 2 quarters · filed 2025-11-12 | $3.20M 10-Q · filed 2025-11-12 | $4.40M derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | $1.16M 10-Q · filed 2025-08-12 | $1.99M 10-Q · filed 2025-08-12 | $3.19M derived: sum of 3 quarters · filed 2025-08-12 | $4.36M derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-03-31 | $828.00K 10-Q · filed 2025-05-13 | $2.02M derived: sum of 2 quarters · filed 2025-05-13 | $3.20M derived: sum of 3 quarters · filed 2025-11-12 | $4.17M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $2.37M derived: sum of 2 quarters · filed 2025-11-12 | $3.35M derived: sum of 3 quarters · filed 2025-11-12 | $4.35M 10-K · filed 2025-03-24 |
| 2024-09-30 | $1.17M 10-Q · filed 2025-11-12 | $2.15M derived: sum of 2 quarters · filed 2025-11-12 | $3.15M 10-Q · filed 2025-11-12 | $4.19M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $976.00K 10-Q · filed 2025-08-12 | $1.98M 10-Q · filed 2025-08-12 | $3.02M derived: sum of 3 quarters · filed 2025-08-12 | $3.80M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.00M 10-Q · filed 2025-05-13 | $2.04M derived: sum of 2 quarters · filed 2025-05-13 | $2.82M derived: sum of 3 quarters · filed 2025-05-13 | $2.98M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $1.82M derived: sum of 2 quarters · filed 2025-03-24 | $1.98M derived: sum of 3 quarters · filed 2025-03-24 | $2.43M 10-K · filed 2025-03-24 |
| 2023-09-30 | $783.00K 10-Q · filed 2024-11-12 | $942.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.39M 10-Q · filed 2024-11-12 | $1.50M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $159.00K 10-Q · filed 2024-08-12 | $605.00K 10-Q · filed 2024-08-12 | $717.00K derived: sum of 3 quarters · filed 2024-08-12 | $793.00K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $446.00K 10-Q · filed 2024-05-13 | $558.00K derived: sum of 2 quarters · filed 2024-05-13 | $634.00K derived: sum of 3 quarters · filed 2024-05-13 | |
| 2022-12-31 | $112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $188.00K derived: sum of 2 quarters · filed 2024-03-25 | $377.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | $76.00K 10-Q · filed 2023-11-13 | $265.00K 10-Q · filed 2023-11-13 | ||
| 2022-03-31 | $189.00K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $500.00K 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Apyx Medical Corp (APYX) | United States | $0.120B | -21.85 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |